At this year’s conference, pharmaphorum editor-in-chief Jonah Comstock caught up with Catherine Owen Adams, the CEO of Acadia ...

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...

Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...

Analysts at RBC Capital Markets have predicted twice-yearly lenacapavir could become a $2 billion product, and become a key ...

A lawsuit filed in the Singapore International Commercial Court is seeking $830 million in damages from KBP, with Novo ...

In his first speech since being appointed Health and Human Services Secretary, Robert F Kennedy Jr pledged to investigate the ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

The 21st century pharmaceutical and biotech sector has come a long way from its roots in 19th century pharmacy. pharmaphorum looks at its evolution over the centuries. The roots of the ...

AstraZeneca and Merck & Co's Lynparza has been the undisputed market leader in the PARP inhibitor category for some years, but would-be competitors continue to chip away at its market share.

The FDA has approved new versions of Pfizer/BioNTech's Comirnaty and Moderna's Spikevax COVID-19 vaccines that target the Omicron KP.2 strain of SARS-CoV-2 which was dominant in the US in recent ...

The pharmaceutical industry is among the most heavily regulated in the world – and with increased globalisation and the enhanced understanding of risk, regulation requirements will continue to grow.

As the race to deliver personalised engagement at scale heats up, artificial intelligence (AI) has become the critical differentiator for pharma companies, turning vast data streams into ...